Skip to main content

Advertisement

Table 2 Comparison of patient and clinical characteristics based on presence of specific ICD codes

From: Validation of diagnosis codes to identify side of colon in an electronic health record registry

Characteristic, n (%) Colon cancer patients with specific ICD codes N = 5940 Colon cancer patients without specific ICD codes N = 3463
Age at metastatic diagnosis (years), median (IQR) 66.0 (56.0–75.0) 66.0 (57.0–75.0)
Age at metastatic diagnosis, years
 18–34 72 (1.2) 46 (1.3)
 35–49 650 (10.9) 353 (10.2)
 50–64 2014 (33.9) 1148 (33.2)
  ≥ 65 3204 (53.9) 1916 (55.3)
Sex
 Female 2771 (46.6) 1614 (46.6)
 Male 3169 (53.4) 1848 (53.4)
 Unknown 0 (0) 1 (< 0.1)
Region
 Northeast 1329 (22.4) 826 (23.9)
 Midwest 1214 (20.4) 412 (11.9)
 South 2263 (38.1) 1074 (31.0)
 West 826 (13.9) 643 (18.6)
 Other/unknown 308 (5.2) 508 (14.7)
Year of mCRC diagnosis
 2011 457 (7.7) 350 (10.1)
 2012 795 (13.4) 602 (17.4)
 2013 1218 (20.5) 838 (24.2)
 2014 1359 (22.9) 792 (22.9)
 2015 1547 (26.0) 679 (19.6)
 2016 564 (9.5) 202 (5.8)
Practice type
 Community 5851 (98.5) 3072 (88.7)
 Academic 89 (1.5) 391 (11.3)
Stage at diagnosis
 0–I 115 (1.9) 84 (2.4)
 II 629 (10.6) 364 (10.5)
 III 1408 (23.7) 839 (24.2)
 IV 3639 (61.3) 1988 (57.4)
 Unknown 149 (2.5) 188 (5.4)
Tumor site
 Left sidea 3061 (51.5) NA
 Right side 2377 (40.0) NA
 Transverse colon 477 (8.0) NA
 Multiple sides 25 (0.4) NA
Number of visits post diagnosis, median (Q1, Q3)
 Any 31 (11, 64) 31 (10, 70)
 Lab 1 (0, 6) 1 (0, 5)
 Treatment 14 (2, 34) 12 (1, 35)
 Office 8 (3, 18) 9 (3, 20)
 Other 0 (0, 0) 0 (0, 0)
 Non-facility 0 (0, 0) 0 (0, 0)
 Radiology 1 (1, 1) 1 (1, 1)
 Missing 21 (0.4) 21 (0.6)
Line of therapy (ever in database), including maintenance
 1 L 4864 (81.9) 2729 (78.8)
 2 L 2252 (37.9) 1341 (38.7)
 3 L 986 (16.6) 642 (18.5)
 4 L 399 (6.7) 265 (7.7)
1 L treatment regimens (non-maintenance)
 FOLFOX 2537 (52.2)b 1367 (50.1)b
 FOLFIRI 903 (18.6)b 533 (19.5)b
 FOLFOXIRI 45 (0.9)b 31 (1.1)b
 Bevacizumab-containing 2736 (56.2)b 1485 (64.4)b
Biomarker status
 KRAS tested 4004 (67.4) 2216 (64.0)
  KRAS Positive 925 (41.1)c 449 (43.1)c
 NRAS tested 1070 (18.0) 466 (13.5)
  NRAS Positive 36 (4.6)c 13 (4.2)c
 BRAF tested 1333 (22.4) 648 (18.7)
  BRAF Positive 101 (11.7)c 38 (10.3)c
  1. 1 L First-line, FOLFIRI Leucovorin/5-fluorouracil/irinotecan, FOLFOX Leucovorin/5-fluorouracil/oxaliplatin, FOLFOXIRI Leucovorin/5-fluorouracil/oxaliplatin/irinotecan, ICD International Classification of Diseases, mCRC Metastatic colorectal cancer, NA Not applicable, Q1 Quarter 1
  2. aIncludes patients with ICD codes for rectal cancer. bPercentage is based on number of patients who have a first line of therapy. cPercentage is based on number of patients who have a record of being tested